22.70Open22.70Pre Close0 Volume50 Open Interest145.00Strike Price0.00Turnover518.64%IV51.83%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry22.70Extrinsic Value100Contract SizeAmericanOptions Type-0.1377Delta0.0010Gamma11.19Leverage Ratio-2.5161Theta-0.0138Rho-1.54Eff Leverage0.0897Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet